Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321698 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00321698 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00321698, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given together with radiation therapy and to see how well they work in treating patients who are undergoing surgery for high-risk localized prostate cancer.
Interventions
- RADIATION Intensity-Modulated Radiation Therapy (IMRT)
- DRUG Docetaxel+IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-04-21 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321698
The ClinicalTrials.gov registry entry for NCT00321698 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intensity-Modulated Radiation Therapy (IMRT) is the first listed.
NCT00321698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321698 about?
NCT00321698 is a clinical study titled "Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with chemotherapy before...
What is the current status of trial NCT00321698?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-04-21. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT00321698?
The interventions under investigation include: Intensity-Modulated Radiation Therapy (IMRT) (RADIATION), Docetaxel+IMRT (DRUG).
Who is sponsoring clinical trial NCT00321698?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.